| Detailed information |
|---|
| CancerLivER ID | 2041 |
| Biomarker | AFP |
| Biomarker Name/Symbol (given in Publication) | AFP |
| Biomolecule | Protein |
| Subject | Human |
| Degree of Validity | HCCS1 promoter methylation for discriminating patients with HCC from CHB and validated on independent dataset |
| Experimental Condition | HCC vs CHB (Chronic hepatitis B); significantly associated with tumor node-metastasis (TNM) stage |
| Cancer type | Hepatocellular carcinoma, Chronic hepatitis B |
| Regulation | NA |
| Level of significance | p < 0.001 |
| Source | Serum |
| PMID | 28189396 |
| Type of Biomarker | Diagnostic and Prognostic |
| Pathway | pro-apoptotic pathway |
| Cohort | 120 patients with HCC, 146 patients with chronic hepatitis B (CHB) and 27 healthy controls (HCs) in training daatset and 63 patients with HCC and 44 patients with CHB in validation dataset. |
| Sensitivity | 55.00% |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | Human HCC and Human CHB (Chronic hepatitis B) |
| Year of Publication | 2017 |
| Clinical trial | YES |
| NCT No# (Clinical trial) | NCT00005629,NCT03132792,NCT00513461,NCT00093548,NCT01350167,NCT02435433,NCT02072356,NCT02582918,NCT02232490,NCT01128803,NCT02312817,NCT01849588,NCT03156582,NCT03533582,NCT03767764,NCT01078311,NCT03493763,NCT00980460,NCT00629421,NCT01392131,NCT0174764 |